March 5, 2009 – MDS Nordion, a leading provider of medical isotopes and radiopharmaceuticals, will showcase an improved administration system for TheraSphere, Yttrium-90 Microsphere (Y-90), a targeted internal radiation therapy for patients with inoperable, primary liver cancer, during the upcoming Society of Interventional Radiology 2009 (SIR 2009) scientific meeting in San Diego, CA.

The enhancements to the administration system allow for safer, faster and more efficient administration of TheraSphere, providing better treatment delivery for patients.

The simplified design of the administration system makes TheraSphere even easier to use for physicians. It has fewer parts, is easier to assemble, requires less handling, and reduces set-up time for physicians by approximately 50 per cent.

The disposable tubing and tubing connections have been re-designed to minimize barriers and optimize the fluid pathway, which is significant for delivery of small particle technology. These improvements optimize dose delivery, providing enhanced safety and ease of use for both medical staff and patients.

"Overall, MDS Nordion incorporated smart enhancements to facilitate the safe and effective delivery of TheraSphere including optimizing access to the dose vial and improving the overall internal flow of the therapy to the affected cells," said David Wood, M.D., chief of Interventional Radiology, Banner Good Samaritan Medical Center, Phoenix, AZ. "These upgrades make the administration of TheraSphere to our patients safer and easier."

May Wahab, M.D., associate professor of Radiation Oncology, Department of Radiation Oncology, Sylvester Cancer Center, Miller School of Medicine at University of Miami Hospital said that TheraSphere is the result of advanced technology allowing incorporation of radiation-emitting Yttrium into glass microbeads.

"The improvements made to the administration system will make delivering TheraSphere much easier and far more efficient and is an exciting development (for the medical community)," noted Dr. Wahab.

For more information: www.mdsnordion.com


Related Content

News | Women's Health

Nov. 3, 2025 — —A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 ...

Time November 04, 2025
arrow
Feature | Kyle Hardner

Radiotherapy contributes to about 40% of all cancer cures but still lags behind systemic therapy in funding and ...

Time October 21, 2025
arrow
News | Prostate Cancer

Sept. 26, 2025 — A new fast and convenient approach to scintigraphy-based monitoring allows physicians to efficiently ...

Time October 03, 2025
arrow
News | Radiopharmaceuticals and Tracers

Sept. 20, 2025 — A promising new PET tracer can visualize a protein that is commonly overexpressed in triple-negative ...

Time September 18, 2025
arrow
News | Radiation Oncology

Sept. 02, 2025 — Alpha Tau Medical Ltd., the developer of the alpha-radiation cancer therapy Alpha DaRT has announced ...

Time September 05, 2025
arrow
News | Radiation Oncology

May 2, 2025 — GE HealthCare has announced an intended expansion of its radiation oncology portfolio as well as the ...

Time May 03, 2025
arrow
News | Radiology Education

April 21, 2025 — On June 20, the American Society of Radiologic Technologists (ASRT) will award Life Member status to ...

Time April 21, 2025
arrow
News | Radiology Business

April 16, 2025 — According to a new report, the U.S. Radiotherapy Market is projected to reach $2.49 billion by 2030 ...

Time April 17, 2025
arrow
News | ASTRO

March 14, 2025 — Another pivotal milestone in the nation’s fight against cancer recently took place with the ...

Time March 17, 2025
arrow
News | Computed Tomography (CT)

Royal Philips recently received 510(k) clearance from the US Food and Drug Administration (FDA) for its detector-based ...

Time November 13, 2024
arrow
Subscribe Now